Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer

Oral Oncology

Volumn 43, Issue 8, 2007, Pages 749-756

  Hasegawa, Yasuhisa ^a   Goto, Mitsuo ^b   Hanai, Nobuhiro ^c   Ijichi, Kei ^c   Adachi, Makoto ^a   Terada, Akihiro ^a   Hyodo, Ikuo ^a   Ogawa, Tetsuya ^a   Furukawa, Tomoko ^d  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^c NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^d SRL INC   (Japan)

Author keywords

5 FU; Cisplatin; Head and neck cancer; Histoculture drug response assay; In vitro chemosensitivity

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DETERMINATION; DRUG INHIBITION; DRUG RESPONSE; FEMALE; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOPHARYNX CANCER; IN VITRO STUDY; LARYNX CANCER; LYMPH NODE METASTASIS; MALE; MOUTH CANCER; OROPHARYNX CANCER; PRIORITY JOURNAL; SALIVARY GLAND CANCER; SQUAMOUS CELL CARCINOMA; TISSUE CULTURE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 34547854346     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2006.09.003     Document Type: Article

References (39)

1. Vokes E.E., Weichselbaum R.R., Lippman S.M., and Hong W.K. Head and neck cancer. New Engl J Med 328 3 (1993) 184-194
2. Forastiere A., Koch W., Trotti A., and Sidransky D. Head and neck cancer. New Engl J Med 345 26 (2001) 1890-1900
3. Pignon J.P., Bourhis J., Domenge C., and Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 355 9208 (2000) 949-955 [MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer]
4. Shiga H., Heath E.I., Rasmussen A.A., Trock B., Johnston P.G., Forastiere A.A., et al. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res 5 12 (1999) 4097-4104
5. Spaulding M.B., Fischer S.G., and Wolf G.T. Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. J Clin Oncol 12 8 (1994) 1592-1599 [The Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group]
6. Hamburger A.W., and Salmon S.E. Primary bioassay of human tumor stem cells. Science 197 4302 (1997) 461-463
7. Hoffman R.M. In vitro sensitivity assays in cancer: a review, analysis, and prognosis. J Clin Lab Anal 5 2 (1991) 133-143
8. Von Hoff D.D. He's not going to talk about in vitro predictive assays again, is he?. J Natl Cancer Inst 82 2 (1990) 96-101
9. Hoffman R.M. Three-dimensional histoculture: origins and applications in cancer research. Cancer Cells 3 3 (1991) 86-92
10. Hoffman R.M. To do tissue culture in two or three dimensions? That is the question. Stem Cells 11 2 (1993) 105-111
11. Furukawa T., Kubota T., Watanabe M., Takahara T., Yamaguchi H., Takeuchi T., et al. High in vitro-in vivo correlation of drug response using sponge-gel-supported three-dimensional histoculture and the MTT end point. Int J Cancer 51 3 (1992) 489-498
12. Furukawa T., Kubota T., and Hoffman R.M. Clinical applications of the histoculture drug response assay. Clin Cancer Res 1 3 (1995) 305-311
13. Furukawa T., Kubota T., Tanino H., Oura S., Yuasa S., Murate H., et al. Chemosensitivity of breast cancer lymph node metastasis compared to the primary tumor from individual patients tested in the histoculture drug response assay. Anticancer Res 20 5C (2000) 3657-3658
14. Hirano Y., Kageyama S., Ushiyama T., Suzuki K., and Fujita K. Clinical usefulness of chemotherapy based on an in vitro chemosensitivity test in urothelial cancer patients. Anticancer Res 21 6A (2001) 4061-4066
15. Morioka H., Yabe H., Morii T., Yamada R., Kato S., Yuasa S., and Yano T. In vitro chemosensitivity of human soft tissue sarcoma. Anticancer Res 21 6A (2001) 4147-4151
16. Ohie S., Udagawa Y., Kozu A., Komuro Y., Aoki D., Nozawa S., et al. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide. Anticancer Res 20 3B (2000) 2049-2054
17. Suda S., Akiyama S., Sekiguchi H., Kasai Y., Ito K., and Nakao A. Evaluation of the histoculture drug response assay as a sensitivity test for anticancer agents. Surg Today 32 6 (2002) 477-481
18. Tanino H., Oura S., Hoffman R.M., Kubota T., Furukawa T., Arimoto J., et al. Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay. Anticancer Res 21 6A (2001) 4083-4086
19. Ariyoshi Y., Shimahara M., and Tanigawa N. Study on chemosensitivity of oral squamous cell carcinomas by histoculture drug response assay. Oral Oncol 39 7 (2003) 701-707
20. Robbins K.T., Connors K.M., Storniolo A.M., Hanchett C., and Hoffman R.M. Sponge-gel-supported histoculture drug-response assay for head and neck cancer. Correlations with clinical response to cisplatin. Arch Otolaryngol Head Neck Surg 120 3 (1994) 288-292
21. Singh B., Li R., Xu L., Poluri A., Patel S., Shaha A.R., et al. Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck 24 5 (2002) 437-442
22. Itaya M., Yoshimoto J., Kojima K., and Futagawa S. Usefulness of p53 protein, Bcl-2 protein and Ki-67 as predictors of chemosensitivity of malignant tumors. Oncol Rep 6 3 (1999) 675-682
23. Sobin L.H., and Wittekind C. UICC TNM classification of malignant tumors. 6th ed. (2002), John Wiley & Sons Inc., New York
24. Shanmugaratnam K. Histological typing of tumours of the upper respiratory tract and ear. 2nd ed. International histological classification of tumours (1991), Springer-Verlag, Berlin
25. Furukawa T., Kubota T., Watanabe M., Kase S., Takahara T., Yamaguchi H., et al. Chemosensitivity testing of clinical gastrointestinal cancers using histoculture and the MTT end-point. Anticancer Res 12 5 (1992) 1377-1382
26. Blumenthal R.D. An overview of chemosensitivity testing. Methods Mol Med 110 (2005) 3-18
27. Kubota T., Sasano N., Abe O., Nakao I., Kawamura E., Saito T., et al. Potential of the histoculture drug-response assay to contribute to cancer patient survival. Clin Cancer Res 1 12 (1995) 1537-1543
28. Becker F.F. Cancer, a comprehensive treatise. Chemotherapy vol. 5 (1977), Plenum Press, New York
29. Bonadonna G., and Cuna G.R. Handbook of medicine oncology. 3rd ed. (1988), Masson S. p. A., Milano
30. Holland J.F., and Frei III E. Cancer medicine. 6th ed. (2003), BC Decker Inc., Ontario
31. Al-Sarraf M. Head and neck cancer: chemotherapy concepts. Semin Oncol 15 1 (1988) 70-85
32. Grose W.E., Lehane D.E., Dixon D.O., Fletcher W.S., and Stuckey W.J. Comparison of methotrexate and cisplatin for patients with advanced squamous cell carcinoma of the head and neck region: a Southwest Oncology Group Study. Cancer Treat Rep 69 6 (1985) 577-581
33. Hong W.K., Schaefer S., Issell B., Cummings C., Luedke D., Bromer R., et al. A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer 52 2 (1983) 206-210
34. Jacobs C., Bertino J.R., Goffinet D.R., Fee W.E., and Goode R.L. 24-hour infusion of cis-platinum in head and neck cancers. Cancer 42 5 (1978) 2135-2140
35. Jacobs C., Lyman G., Velez-Garcia E., Sridhar K.S., Knight W., Hochster H., et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10 2 (1992) 257-263
36. Liverpool Head and Neck Oncology Group. A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Br J Cancer 61 2 (1990) 311-315
37. Sako K., Razack M.S., and Kalnins I. Chemotherapy for advanced and recurrent squamous cell carcinoma of the head and neck with high and low dose cis-diamminedichloroplatinum. Am J Surg 136 4 (1978) 529-533
38. Amer M.H., Al-Sarraf M., and Vaitkevicius V.K. Factors that affect response to chemotherapy and survival of patients with advanced head and neck cancer. Cancer 43 6 (1979) 2202-2206
39. Esaki T., Nakano S., Masumoto N., Fujishima H., and Niho Y. Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST-1 human squamous carcinoma cell line. Int J Cancer 65 4 (1996) 479-484